<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01003093</url>
  </required_header>
  <id_info>
    <org_study_id>THYB-01</org_study_id>
    <secondary_id>Eudract number: TEST-001599-14</secondary_id>
    <nct_id>NCT01003093</nct_id>
  </id_info>
  <brief_title>A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis(TB) Subunit Vaccine</brief_title>
  <acronym>THYB-01</acronym>
  <official_title>A Safety and Immunogenicity Phase 1 Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31) Administered at 0 and 2 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Statens Serum Institut</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Statens Serum Institut</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety profile of an adjuvanted TB subunit
      vaccine administered at 0 and 2 months in healthy BCG-unvaccinated volunteers with no prior
      history of TB disease or known prior exposure to TB
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical examination. Local adverse events. Systemic adverse events. Laboratory safety tests including urine safety tests.</measure>
    <time_frame>From the first vaccination until 8 months after the first vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection by ELISPOT of IFN gamma spot-forming cells in PBMC. Detection by ELISA of IFN gamma production in supernatants of PBMC. Detection of humoral response (IgG) by ELISA.</measure>
    <time_frame>From first vaccination until 36 months after first vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Antigen group + high adjuvans</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The antigen group + high adjuvans group received two injections of antigen (Ag85B + ESAT-6) + IC31 (500 nmol KLK + 20 nmol ODN1a) two months apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antigen group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The antigen group received two injections of antigen (Ag85B + ESAT-6) two months apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antigen + low adjuvans group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The antigen group + low adjuvans group received two injections of antigen (Ag85B + ESAT-6) + IC31 (100 nmol KLK + 4 nmol ODN1a) two months apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>50 microgram antigen (Ag85B + ESAT-6)</intervention_name>
    <description>0.5 mL suspension for injection x 2 with 2 months interval</description>
    <arm_group_label>Antigen group</arm_group_label>
    <other_name>Antigen H1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>50 microgram antigen (Ag85B + ESAT-6) + 100 nmol KLK + 4 nmol ODN1a</intervention_name>
    <description>0.5 mL suspension for injection x 2 with 2 months interval</description>
    <arm_group_label>Antigen + low adjuvans group</arm_group_label>
    <other_name>Antigen H1 + IC31</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>50 microgram antigen (Ag85B + ESAT-6) + 500 nmol KLK + 20 nmol ODN1a</intervention_name>
    <description>0.5 mL suspension for injection x 2 with 2 months interval</description>
    <arm_group_label>Antigen group + high adjuvans</arm_group_label>
    <other_name>Antigen H1 + IC31</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  Healthy based on medical examination/history at the inclusion

          -  Age between 18 and 55 years

          -  Signed informed consent

          -  Prepared to grant authorized persons access to the medical records

          -  The volunteer is likely to comply with instructions

        Exclusion Criteria:

          -  Known exposure to TB before (or expected during) the trial

          -  Prior BCG vaccination

          -  Granulomatous disease (by chest X-ray, autoimmune screen)

          -  Vaccinated with live vaccine 3 months before first vaccination

          -  Administration of immune modulating drugs (steroids, immunosuppressive drugs or
             immunoglobulins) 3 months before the first vaccination

          -  HBV, HCV or HIV sero-positive (HBsAg, HBsAb, HBc total and IgM ab and HCV, HIV-1 and
             HIV2 ab)

          -  Participation in other clinical trials

          -  Positive Mantoux or QuantiFERON-TB Gold

          -  Known hypersensitivity to any of the vaccine components

          -  Laboratory parameters outside of normal ranges considered clinically relevant
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaap van Dissel, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leiden University Medical Centre</name>
      <address>
        <city>Leiden</city>
        <state>RC Leiden</state>
        <zip>2300</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2009</study_first_submitted>
  <study_first_submitted_qc>October 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2009</study_first_posted>
  <last_update_submitted>January 18, 2013</last_update_submitted>
  <last_update_submitted_qc>January 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Ag85B</keyword>
  <keyword>ESAT-6</keyword>
  <keyword>IC31</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

